1. Home
  2. BMBL vs DSGN Comparison

BMBL vs DSGN Comparison

Compare BMBL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bumble Inc.

BMBL

Bumble Inc.

N/A

Current Price

$6.00

Market Cap

783.9M

Sector

Technology

ML Signal

N/A

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

N/A

Current Price

$10.81

Market Cap

853.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BMBL
DSGN
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
783.9M
853.8M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
BMBL
DSGN
Price
$6.00
$10.81
Analyst Decision
Hold
Strong Buy
Analyst Count
9
8
Target Price
$4.21
★ $21.57
AVG Volume (30 Days)
★ 11.7M
416.0K
Earning Date
11-09-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $965,658,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.44
$6.81
52 Week High
$6.00
$17.25

Technical Indicators

Market Signals
Indicator
BMBL
DSGN
Relative Strength Index (RSI) 87.42 47.71
Support Level $2.62 $9.83
Resistance Level $6.00 $11.43
Average True Range (ATR) 0.03 0.61
MACD -0.10 0.08
Stochastic Oscillator 92.86 60.94

Price Performance

Historical Comparison
BMBL
DSGN

About BMBL Bumble Inc.

Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: